TUDCA has attracted over 27,000 Google searches per month as of July 2026 — driven by research showing it works as a chemical chaperone that reduces endoplasmic reticulum (ER) stress in the liver, brain, and metabolic tissues. This mechanism is independent of its bile acid function and has implications for neurodegenerative diseases, metabolic disorders, and liver conditions. TUDCA (tauroursodeoxycholic acid, CAS 14605-22-2) is the taurine conjugate of UDCA — a modification that increases water solubility and enables it to cross the blood-brain barrier, unlike its parent compound.
TUDCA is not FDA-approved as a prescription drug. It is sold in the United States and internationally as a dietary supplement available over the counter (OTC). This distinguishes it from its parent compound UDCA (ursodiol), which holds FDA approval for primary biliary cholangitis (PBC) and gallstone dissolution. TUDCA does not hold a formal FDA GRAS determination; its OTC status is based on its presence as a minor endogenous bile acid in humans (2-4% of total biliary bile acids) and the long clinical safety record of UDCA.
Interest in TUDCA has grown over the past decade, driven by preclinical research showing its activity as a chemical chaperone that reduces endoplasmic reticulum (ER) stress, independent of its bile acid function. This mechanism has implications for neurodegenerative diseases, metabolic disorders, and liver conditions. As of July 2026, Google search volume for "TUDCA" exceeds 27,000 searches per month.
TUDCA works through several pathways. The four main mechanisms are:
TUDCA stabilizes protein folding in the endoplasmic reticulum lumen by binding to exposed hydrophobic regions of misfolded proteins. This reduces the unfolded protein response (UPR), a cellular stress pathway triggered when ER protein folding capacity is overwhelmed. Chronic ER stress is implicated in insulin resistance, beta-cell dysfunction in type 2 diabetes, and neurodegenerative protein aggregation diseases. Research published in Science (Ozcan et al., 2006) demonstrated that TUDCA treatment normalized hyperglycemia and restored insulin sensitivity in obese and diabetic mice by reducing ER stress in the hypothalamus, liver, and adipose tissue.
TUDCA inhibits the intrinsic (mitochondrial) apoptotic pathway through three specific actions: (1) blocking Bax translocation from the cytosol to the mitochondrial outer membrane, (2) preventing mitochondrial cytochrome c release into the cytoplasm, and (3) reducing activation of caspase-3, caspase-9, and caspase-12. These effects have been confirmed in hepatocyte models exposed to hydrophobic bile acids, ethanol, and TGF-beta, as well as in neuronal cell models. Unlike broad-spectrum caspase inhibitors, TUDCA acts upstream at the mitochondrial level, preserving cellular energy metabolism while preventing apoptosis.
TUDCA directly inhibits reactive oxygen species (ROS) production and upregulates endogenous antioxidant defenses. In primary hepatocyte cultures, TUDCA at concentrations of 50-200 µM reduced ROS levels by 40-60% following oxidative challenge. This effect is partially mediated through PI3K/Akt pathway activation, which promotes cell survival and suppresses pro-oxidant enzyme expression.
TUDCA suppresses NF-kB activation and reduces expression of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. In a murine colitis model, TUDCA administration reduced intestinal inflammation scores and preserved epithelial barrier integrity. In neural tissue, TUDCA attenuates microglial activation, which contributes to its neuroprotective profile.
The most clinical evidence for TUDCA is in liver disease. A 3-month clinical trial in chronic hepatitis patients found that TUDCA supplementation reduced alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) levels compared to baseline. The hepatoprotective mechanism combines anti-apoptotic activity (protecting hepatocytes from bile acid-induced death), choleretic effects (stimulating bile flow), and direct antioxidant action. For cholestatic liver diseases, TUDCA's ability to displace toxic hydrophobic bile acids from the bile acid pool provides additional benefit distinct from simple ER stress reduction.
Three lines of preclinical evidence support TUDCA's neuroprotective potential:
As of mid-2026, the sole completed Phase 3 trial for a neurological indication ( the TUDCA-ALS trial (NCT03800524) ) did not demonstrate efficacy on its primary endpoint. All other neuroprotective evidence remains preclinical except the small ALS pilot trial and a Phase 1/2 progressive MS safety trial (2025, n=47).
TUDCA improves insulin sensitivity through ER stress reduction in peripheral tissues. In a proof-of-concept human study, TUDCA 1,750 mg/day for 4 weeks increased hepatic insulin sensitivity by approximately 30% and muscle insulin sensitivity by approximately 25% in obese individuals, as measured by hyperinsulinemic-euglycemic clamp. This makes TUDCA relevant for metabolic syndrome and type 2 diabetes research, though long-term outcome data are lacking.
| Parameter | TUDCA | UDCA |
|---|---|---|
| Full Name | Tauroursodeoxycholic Acid | Ursodeoxycholic Acid |
| FDA Status | Dietary supplement (OTC) | FDA-approved prescription drug |
| Water Solubility | Higher (taurine conjugate) | Lower (unconjugated) |
| Blood-Brain Barrier Penetration | Documented in animal models | Minimal to none |
| Clinical Evidence Level | Limited human trials; strong preclinical | Multiple phase III RCTs; FDA approved |
| Typical Human Dose | 250-1,500 mg/day | 8-15 mg/kg/day |
| Insurance Coverage | Not covered (supplement) | Covered for approved indications |
| Cost (approximate) | $0.50-$2.00/day (supplement) | $3-$8/day (generic); $15-$30/day (brand) |
TUDCA and UDCA are structurally related but not interchangeable. TUDCA's taurine conjugation confers higher aqueous solubility and the ability to cross the blood-brain barrier, a property that drives its investigation in neurological conditions where UDCA is ineffective. For liver indications, UDCA has the advantage of more clinical trial data and FDA labeling, while TUDCA's liver evidence, though positive, comes mainly from smaller studies. See our detailed comparison at TUDCA vs UDCA: Differences, Benefits & Which to Choose.
China is the largest producer of TUDCA raw material, using the same cholic acid supply chain that supports UDCA manufacturing. When sourcing TUDCA from China, buyers should verify whether the product is pharmaceutical-grade or supplement-grade, since this affects pricing, regulatory acceptance, and quality documentation. As a TUDCA supplier China, KingWish provides TUDCA with full documentation support including CoA, MSDS, and GMP certificates. For buyers seeking tudca powder supplier or exploring buy tudca bulk options, contact our team for specifications and pricing. Common procurement terms include MOQ starting at 25 kg for pharmaceutical-grade material, with smaller trial quantities available for initial quality evaluation.
TUDCA dosing varies significantly by intended use. All dosing recommendations below are based on published clinical literature; they are not medical advice. Anyone considering TUDCA supplementation should consult a licensed healthcare provider.
For detailed dosing guidance, see TUDCA Dosage Guide: Evidence-Based Dosing Recommendations.
TUDCA has a good safety record based on available human data, with some caveats:
Full safety details: TUDCA Side Effects & Safety: What the Research Shows.
TUDCA quality in the supplement market varies widely. As a compound not regulated as a pharmaceutical, TUDCA supplements are not subject to FDA pre-market approval. Key quality considerations include:
For procurement guidance, see How to Source TUDCA: Quality, Suppliers & Procurement Guide.
TUDCA (tauroursodeoxycholic acid) is synthesized from UDCA (ursodeoxycholic acid) through conjugation with taurine. UDCA is extracted and purified from bovine bile, then chemically conjugated with taurine to form TUDCA. The manufacturing process involves four stages: (1) extraction of cholic acid from bovine bile, (2) chemical synthesis through epimerization to UDCA, (3) conjugation with taurine via an amide bond formation reaction, and (4) purification to pharmaceutical or supplement grade (typically over 98% purity by HPLC). An emerging alternative is enzymatic biosynthesis using engineered yeast (Saccharomyces cerevisiae) strains that express 7-alpha-HSDH, 7-beta-HSDH, and BAAT enzymes, achieving TUDCA production directly from CDCA in a single fermentation step, though commercial-scale production still relies mostly on semi-synthetic routes from bovine-derived cholic acid.
TUDCA is primarily used for liver health support and has been studied for multiple therapeutic applications: (1) hepatoprotection in cholestatic liver diseases, where it displaces toxic hydrophobic bile acids and stimulates bile flow; (2) reduction of liver enzymes (ALT, AST) in chronic hepatitis and metabolic liver conditions; (3) neuroprotection in preclinical models of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), based on its ability to cross the blood-brain barrier and reduce endoplasmic reticulum stress; (4) metabolic benefits including improved insulin sensitivity as demonstrated in proof-of-concept human studies. TUDCA is not FDA-approved as a standalone prescription drug. It is sold as a dietary supplement over the counter and is also used as a pharmaceutical intermediate in the manufacture of finished drug products. As of July 2026, the sole completed Phase 3 clinical trial for a neurological indication (TUDCA-ALS, NCT03800524) did not meet its primary endpoint, and no new FDA approvals for TUDCA have been issued.
| CAS Number | 14605-22-2 |
|---|---|
| Molecular Formula | C26H45NO6S |
| Molecular Weight | 499.7 |
| Regulatory Status | Dietary Supplement (OTC) |
| Typical Dose | 250-500 mg/day |
| Mechanism Class | Chemical Chaperone / Bile Acid |
| Parent Compound | Ursodeoxycholic Acid (UDCA) |